Guoxin Securities pointed out that due to the increase in th...

Guoxin Securities pointed out that due to the increase in the incidence of shingles year by year and the heavy burden of disease, the shingles vaccine market prospects are optimistic. GlaxoSmithKline's Shingrix vaccine grew rapidly after launch and could drive the overall market further development. It is predicted that in 2032, the vaccination rate for people aged 50 and above in China will reach 15%, and the market size is expected to exceed 30 billion yuan.